Literature DB >> 11971045

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

I S J Merkies1, P I M Schmitz, F G A van der Meché, J P A Samijn, P A van Doorn.   

Abstract

OBJECTIVES: To determine the validity, reliability, and responsiveness of a new overall disability sum score in immune mediated polyneuropathies.
METHODS: Three impairment measures (MRC sum score, sensory sum score, grip strength (Vigorimeter)) and three disability scales (an overall disability sum score (ODSS), Hughes' functional scale (f score), Rankin scale) were assessed in a cross sectional group of 113 clinically stable patients (83 with Guillain-Barré syndrome, 22 with chronic inflammatory demyelinating polyneuropathy (CIDP), eight with a gammopathy related polyneuropathy). The ODSS was also used serially in 20 patients with recently diagnosed Guillain-Barré syndrome (n = 7) or CIDP (n = 13) and changing clinical conditions. Multiple regression studies were performed to compare the impact of impairment disturbances (independent variables) on the various disability scales (dependent variable).
RESULTS: Moderate to good construct validity (stable group: Spearman's rank test (absolute values), r = 0.41-0.79; longitudinal group: multiple correlation coefficient, R = 0.69-0.89; p < 0.006 for all associations) and reliability (intraclass correlation coefficient, R = 0.90-0.95; p < 0.0001) were demonstrated for the ODSS. Its SRM values were high (> 0.8), indicating good responsiveness. Impairment measures accounted for a higher variance proportion of the ODSS compared with the f score and Rankin (R = 0.64 v 0.56 and 0.45, respectively).
CONCLUSIONS: All clinimetric requirements were met by the overall (arm and leg) disability sum score in immune mediated polyneuropathies. Its use is therefore suggested in evaluating immune mediated polyneuropathies.

Entities:  

Mesh:

Year:  2002        PMID: 11971045      PMCID: PMC1737884          DOI: 10.1136/jnnp.72.5.596

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome.

Authors:  R P Kleyweg; F G van der Meché; P I Schmitz
Journal:  Muscle Nerve       Date:  1991-11       Impact factor: 3.217

Review 3.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

5.  Measuring change over time: assessing the usefulness of evaluative instruments.

Authors:  G Guyatt; S Walter; G Norman
Journal:  J Chronic Dis       Date:  1987

6.  Guillain-Barré syndrome: psychosocial aspects of management.

Authors:  S J Eisendrath; M A Matthay; J A Dunkel; J K Zimmerman; R B Layzer
Journal:  Psychosomatics       Date:  1983-05       Impact factor: 2.386

7.  Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; J P Samijn; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

8.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.

Authors:  I S Merkies; P I Schmitz; F G van der Meché; P A van Doorn
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

9.  Comparisons of five health status instruments for orthopedic evaluation.

Authors:  M H Liang; A H Fossel; M G Larson
Journal:  Med Care       Date:  1990-07       Impact factor: 2.983

10.  Controlled trial prednisolone in acute polyneuropathy.

Authors:  R A Hughes; J M Newsom-Davis; G D Perkin; J M Pierce
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321

View more
  58 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

3.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Authors:  R C Graham; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

4.  Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

Authors:  Hubertus Köller; Michael Schroeter; Heinrich Feischen; Hans-Peter Hartung; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-08-11       Impact factor: 4.849

5.  Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Y-C Chan; D C Allen; D Fialho; K R Mills; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

6.  Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016.

Authors:  Emilio Dirlikov; Chelsea G Major; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge L Muñoz-Jordan; Candimar Colon-Sanchez; Myriam Garcia; Marangely Olivero-Segarra; Graciela Malave; Gloria M Rodríguez-Vega; Dana L Thomas; Stephen H Waterman; James J Sejvar; Carlos A Luciano; Tyler M Sharp; Brenda Rivera-García
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

7.  New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability.

Authors:  Elisabeth A Cats; W-Ludo van der Pol; Sanne Piepers; Nicoll C Notermans; R M van den Berg-Vos; L H van den Berg
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

Review 8.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

9.  Connecting impairment, disability, and handicap in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

10.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.